BeyondSpring (BYSI) Other Accumulated Expenses (2015 - 2026)
BeyondSpring (BYSI) posted Other Accumulated Expenses of $937000.0 for Q1 2026, up 13.99% sequentially from $822000.0 in Q4 2025, and down 31.3% YoY from $1.4 million in Q1 2025.
BeyondSpring (BYSI) Other Accumulated Expenses (2015 - 2026) Analysis & Trends
BeyondSpring has reported Other Accumulated Expenses for 12 years, with the latest figure at $937000.0 in Q1 2026.
- Quarterly Other Accumulated Expenses fell 31.3% year-over-year to $937000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $937000.0 (down 31.3% YoY) and the FY2025 annual result came in at $822000.0, up 5.38% from the prior year.
- Other Accumulated Expenses climbed to $937000.0 in Q1 2026 per BYSI's latest filing, from $822000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $5.1 million in Q2 2022 and troughed at $612000.0 in Q2 2025.
- A 5-year average of $1.4 million and a median of $1.1 million in 2023 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses jumped 59.57% in 2022, then sank 78.28% in 2023.
- Over 5 years, Other Accumulated Expenses stood at $1.5 million in 2022, then decreased by 27.96% to $1.1 million in 2023, then dropped by 27.03% to $780000.0 in 2024, then grew by 5.38% to $822000.0 in 2025, then advanced by 13.99% to $937000.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $937000.0, $822000.0, and $676000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | BeyondSpring | 29.85 Mn | 29.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.06 Mn |
| Mar 31, 2026 | 937,000.00 |
| Dec 31, 2025 | 822,000.00 |
| Sep 30, 2025 | 676,000.00 |
| Jun 30, 2025 | 612,000.00 |
| Mar 31, 2025 | 1.36 Mn |
| Dec 31, 2024 | 780,000.00 |
| Jun 30, 2024 | 1.64 Mn |
| Dec 31, 2023 | 1.07 Mn |
| Jun 30, 2023 | 1.10 Mn |
| Dec 31, 2022 | 1.48 Mn |
| Jun 30, 2022 | 5.08 Mn |
| Dec 31, 2021 | 6.17 Mn |
| Sep 30, 2021 | 5.77 Mn |
| Jun 30, 2021 | 3.19 Mn |
| Mar 31, 2021 | 1.92 Mn |
| Dec 31, 2020 | 3.81 Mn |
| Sep 30, 2020 | 1.55 Mn |
| Jun 30, 2020 | 1.46 Mn |
| Mar 31, 2020 | 1.69 Mn |